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While bradykinin (BK) is known to be degraded by angiotensin converting enzyme (ACE),
we have recently discovered that Met-Lys-BK-Ser-Ser is paradoxically activated by ACE.We
designed and evaluated additional “prodrug” peptides extended around the BK sequence
as potential ligands that could be locally activated by vascular or blood plasma peptidases.
BK regenerationwas estimated using the contractility of the human umbilical vein asmodel
of vascular functions mediated by endogenous B2 receptors (B2Rs) and the endocytosis
of the fusion protein B2R-green ﬂuorescent protein (B2R-GFP) expressed in Human
Embryonic Kidney 293 cells. Of three BK sequences extended by a C-terminal dipeptide,
BK-His-Leu had the most desirable proﬁle, exhibiting little direct afﬁnity for the receptor
but a signiﬁcant one for ACE (as shown by competition of [3H]BK binding to B2R-GFP
or of [3H]enalaprilat to recombinant ACE, respectively). The potency of the contractile
effect of this analog on the vein was reduced 18-fold by the ACE inhibitor enalaprilat,
pharmacologically evidencing BK regeneration in situ. BK-Arg, a potential substrate of
arginine carboxypeptidases, had a low afﬁnity for B2Rs and its potency as a contractile
agent was reduced 15-fold by tissue treatment with an inhibitor of these enzymes,
Plummer’s inhibitor. B2R-GFP internalization in response to 100 nM of the extended
peptides recapitulated these ﬁndings, as enalaprilat selectively inhibited the effect of BK-
His-Leu and Plummer’s inhibitor, that of BK-Arg.The two peptidase inhibitors did not affect
BK-induced effects in either assay. The novel C-terminally extended BKs had no or very
little afﬁnity for the kinin B1 receptor (competition of [3H]Lys-des-Arg9-BK binding). The
feasibility of peptidase-activated B2R agonists is illustrated by C-terminal extensions of the
BK sequence.
Keywords: angiotensin converting enzyme, arginine carboxypeptidases, bradykinin, vascular smooth muscle,
B2 receptors for bradykinin
INTRODUCTION
Angiotensin converting enzyme (ACE; ACE1) is an ectopepti-
dase expressed by vascular endothelial cells and speciﬁc renal
epithelial cells; a soluble form in blood plasma also exists since
a fraction of the enzyme is cleaved from the endothelial sur-
face. ACE is the molecular target of an important class of drugs,
the ACE inhibitors, widely used in the therapy of cardiovascular
and renal diseases (Izzo and Weir, 2011). Blocking the metal-
lopeptidase ACE inhibits the conversion of the inactive peptide
angiotensin (Ang) I to the active pressor Ang II via the removal
of the C-terminaldipeptide His-Leu from the substrate. However,
ACE has other peptide substrates that are rather inactivated by
the removal of a C-terminal dipeptide, bradykinin (BK) being a
prominent example. Thus, ACE (kininase II) inhibition has the
potential to potentiate BK effects in vivo, especially at the level
of preformed and widely expressed B2 receptors (B2Rs; Leeb-
Lundberg et al., 2005). There is limited clinical evidence that BK
participates to the anti-hypertensive and other actions of ACE
inhibitors as variable fractions of their effects are abated by the
speciﬁc B2R antagonist icatibant (Gainer et al., 1998; Squire et al.,
2000; Pretorius et al., 2003).
If endogenous BK, especially via its effect on endothelium-
mediated vasorelaxation, has beneﬁcial cardiovascular beneﬁts,
one could wonder whether the administration of the peptide or
of an analog would be clinically feasible in view of the inﬂamma-
tory, algogenic, and diarrhea-promoting effect of BK (Manning
et al., 1982; Duchene and Bader, 2010). There are few preclinical
models where this has been attempted, but they met with apparent
success. Thus, in rodents, the administrationof peptidase-resistant
agonists of the B2R improved pulmonary hypertension and its car-
diac complication and, following myocardial infarction, reduced
the extent of tissue damage and improved cardiac function with
beneﬁcial effects on tissue remodeling (Taraseviciene-Stewart
et al., 2005; Marketou et al., 2010; Potier et al., 2013). All these
effects are postulated to stem from BK-induced endothelium-
mediated vasodilation. An application of a B2R agonist that
deliberately exploited the pro-inﬂammatory effect of BK was the
infusion of labradimil, a BK analog protected against ACE, to
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temporarily open the blood–brain barrier (a potential adjuvant of
the chemotherapy of brain tumors; Packer et al., 2005). Any major
vascular leakage or extravascular effects (such as the stimulation of
afferent nerve terminals or epithelial cells) could be the source of
side effects thatwould preclude the development of B2R agonists as
drugs.
Met-Lys-BK-Ser-Ser was recently identiﬁed as a kinin produced
from the cleavage of high molecular weight kininogen by the neu-
trophil leukocyte protease PR3 (Kahn et al., 2009). As the vascular
pharmacology of this peptide was further explored, it was found
that ACE paradoxically activates it (Gera et al., 2011). The Ser–Ser
C-terminal extension, presumably removed by ACE, drastically
decreases the peptide’s afﬁnity at the B2R, while potential reaction
products Met-Lys-BK, Lys-BK, and BK are all known high afﬁnity
agonists of the B2R. This discovery may inspire a “prodrug” strat-
egy where a therapeutic B2R agonist would be activated only at the
level of vascular endothelial cells, where the circulatory beneﬁts
are generated (Hornig et al., 1997).
This research program seeks to deﬁne a new cardiovascu-
lar drug class, the BK B2R agonists, that will stimulate the
most desirable effects of endothelial B2Rs in intensive care sit-
uations where an intravenous line is available (unstable angina,
myocardial infarction, perhaps decompensated congestive heart
failure) and possibly, in more chronic ailments (e.g., pulmonary
hypertension). Inspired by the discovery of the ACE-mediated
activation of Met-Lys-BK-Ser-Ser, a possible approach to develop
such a new class of drugs is to exploit resident vascular pepti-
dases in a prodrug strategy. We designed and evaluated “prodrug”
peptides extended around the BK sequence as potential lig-
ands of low potency at the B2R, but that could be activated
by vascular peptidases. Starting with BK extended by dipep-
tides as ACE substrates, the concept has been extended to other
potential substrates for alternate peptidases present in the vas-
culature: dipeptidyl peptidase IV (DPP IV; Shah et al., 2011)
and arginine carboxypeptidases (Arg-CP; Sangsree et al., 2003;
Figure 1).
MATERIALS AND METHODS
RADIOLIGAND BINDING COMPETITION ASSAYS
Afﬁnity for the B2R was evaluated using a radioligand binding
competition assay performed at 0◦C in the presence of pep-
tidase inhibitors that included captopril (Houle et al., 2000).
Brieﬂy, the binding of 3 nM [3H]BK (Perkin Elmer Life Sci-
ences; 90 Ci/mmol) to adherent intact Human Embryonic Kidney
(HEK) 293 cells stably expressing the fusion protein rabbit B2R-
green ﬂuorescent protein (B2R-GFP) was applied to construct
binding competition curves for a series of unlabeled peptides.
Other HEK 293a cells that transiently expressed human recom-
binant ACE were used to perform a [3H]enalaprilat binding
assay as described (Koumbadinga et al., 2010; the peACE vec-
tor was a gift from Prof. P. Corvol, Paris, France). A 2 nM
concentration of [3H]enalaprilat was used to generate binding
competition curves for BK and speciﬁc analog, as the ACE sub-
strate BK effectively displaces this radioligand (Koumbadinga
et al., 2010). It was veriﬁed that novel analogs have no afﬁnity at
the kinin B1 receptor (B1R) in a competition assay with the bind-
ing of 1 nM [3H]Lys-des-Arg9-BK (Perkin Elmer Life Sciences;
FIGURE 1 | Extended BK sequences as potential “prodrug”
agonists of the B2R activated by peptidases. BK is itself degraded
by several peptidases that terminate its signaling at B2Rs. ACE:
angiotensin converting enzyme; APP: aminopeptidase P; Arg-CP:
arginine carboxypeptidases; DPP IV: dipeptidyl peptidase-4.
88 Ci/mmol) to HEK 293a cells transiently expressing the human
B1R (B1R-FLAG vector, Morissette et al., 2008; binding assay as in
Gera et al., 2011).
VASCULAR SMOOTH MUSCLE CONTRACTILITY ASSAY
The institutional research ethics board (CHU de Québec)
approved the anonymous use of human umbilical cord segments
obtained after elective cesarean section deliveries. Informed con-
sent was obtained from mothers. Umbilical vein rings, used as
a contractile bioassay for the BK B2R, were prepared and sus-
pended in organ baths and submitted to equilibration in Krebs’
solution as described (Marceau et al., 1994; Gera et al., 2011). The
vascular preparation was used to assess the effect of the pepti-
dase inhibitors (introduced 30 min before the agonist) on the
apparent potency of BK and related peptides. The full cumula-
tive concentration-effect curves were recorded for each peptide;
a large concentration of BK (9.4 μM) was added to record the
maximal contractile effect mediated by the B2Rs for low potency
agonists. Tissues were used only once and discarded; controls
curves were obtained from other vascular rings from the same
vein.
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DESIGN OF C-TERMINALLY EXTENDED BRADYKININ ANALOGS: ACE
SUBSTRATES
BK-Ser-Tyr, BK-His-Leu, BK-Ala-Pro, Arg-Pro-BK, and BK-Arg
were custom synthesized by Peptide 2.0 Inc. (Chantilly, VA, USA)
via standard solid-phase methodology and provided as >98.8%
pure reagents (mass spectroscopy and HPLC analyses). The aim
of the design of the three ﬁrst peptides was to introduce two amino
acids that would be easily and selectively cleaved by the carboxy-
dipeptidase ACE, thus restoring BK, the minimal sequence for
high-afﬁnity B2R activation. At the same time, the C-terminal
addition would ideally decrease the afﬁnity of the 11-mers for the
B2R relative to that of the nonapeptide BK, thus making the reac-
tion with ACE a functional activation one, analogous to the effect
of ACE on Ang I.
The ﬁrst design, BK-Ser-Tyr, was inspired from a study of
peptides from ﬁsh muscle hydrolysate: this empirical approach
identiﬁed a tetrapeptide ending with Ser-Tyr as the most efﬁcient
competitor of ACE enzymatic activity (Balti et al., 2010). The Ser–
Ser C-terminal dipeptide, also found inMet-Lys-BK-Ser-Ser (Gera
et al., 2011), was comparatively less efﬁcacious as an ACE com-
petitor (Balti et al., 2010). Therefore, it was hoped that BK-Ser-Tyr
would compare favorably with Met-Lys-BK-Ser-Ser as a latent B2R
agonist activated by ACE. BK-His-Leu included the C-terminal
dipeptide His-Leu that is removed from Ang I by ACE. The exten-
sion in BK-Ala-Pro is inspired from the structure of captopril,
a high afﬁnity ACE inhibitor that mimics a dipeptide. In addi-
tion, hippuryl-Ala-Pro is an ACE substrate more efﬁcient (higher
kcat/Km) than hippuryl-His-Leu or Ang I itself (Michaud et al.,
1997). Of note, the tetrapeptide Gly-Asp-Ala-Pro was the second
best competitor of ACE in the ﬁsh protein hydrolysate mentioned
above (Balti et al., 2010), further supporting the hypothesis that
BK-Ala-Pro has afﬁnity for ACE.
DESIGN OF OTHER BRADYKININ ANALOGS
Arg-Pro-BK (Figure 1) was designed by introducing the N-
terminal dipeptide of substance P, a known substrate of DPP IV
(Lambeir et al., 2003), at the N-terminus of BK. X-Pro dipeptides
(positions P2 and P1 relative to the sessile bond) are effec-
tively removed from the N-terminus of several peptides by this
serine peptidase, but intact BK is not a signiﬁcant DPP IV sub-
strate due to the presence of Pro3 at the P1’ position (Lambeir
et al., 2003). A potent and highly selective inhibitor of DPP
IV, NVP-DPP728 (Hughes et al., 1999), was exploited in the
pharmacological evaluation of Arg-Pro-BK.
BK-Arg was designed as a potential substrate of Arg-CP, of
which Plummer’s inhibitor (mercaptomethyl-3-guanidinoethyl-
thiopropanoic acid; Calbiochem, La Jolla, CA,USA; Plummer and
Ryan, 1981) is a selective inhibitor. Arg-CP generate des-Arg9-
kinins that are selective agonists of B1Rs; however, des-Arg9-BK
has virtually no afﬁnity for the B2R and only a weak afﬁnity for
the human form of the B1R (Leeb-Lundberg et al., 2005) and any
activation of BK-Arg in the applied bioassays must proceed via the
generation of intact BK.
OTHER DRUGS
Bradykinin was purchased from Bachem (Torrance, CA,
USA). Enalaprilat dehydrate was from Kemprotec Ltd.
(Maltby, Middlesbrough, UK) and NVP-DPP728 (1-[[[2-[(5-
cyanopyridin-2-yl)amino]ethyl]amino]acetyl]-2-cyano-(S)-pyrro
lidine), from Tocris Bioscience (Bristol, UK). The other drugs were
from Sigma-Aldrich (St. Louis, MO, USA).
EFFECT OF AGENTS ON B2R-GFP CYCLING
Human Embryonic Kidney 293 cells stably expressing B2R-GFP at
the level of their plasma membrane exhibit BK-induced endoso-
mal internalization of the ﬂuorescent receptor, maximal 30 min
after stimulation but with gradual recycling to the cell surface
in 1–3 h (Bachvarov et al., 2001; Charest-Morin et al., 2013b). A
microscopic assay of extended BK analogs was based on this sys-
tem and on the fact that the culture medium containing 10%
heat-inactivated fetal bovine serum contains the active soluble
form of ACE that remains the main BK inactivation pathway
in the system (Bachvarov et al., 2001). Arg-CP(s) sensitive to
Plummer’s inhibitor are also found in human plasma and inﬂam-
matory synovial ﬂuid that contains serum proteins (Chercuitte
et al., 1987), suggesting that serum-containing culture medium
may contain this enzymatic activity. HEK 293 cells stably express-
ing B2R-GFP were observed in epiﬂuorescence microscopy at
a 1000× magniﬁcation and photographed using an Olympus
BX51 microscope coupled to a CoolSnap HQ digital camera (ﬁl-
ters for GFP and ﬂuorescein: excitation 460–500 nm, emission
510–560 nm, objective lens 100× oil UPlanApo, Olympus). The
experiments were based on BK or BK analog stimulation of dif-
ferent durations to monitor either the endocytosis of B2R-GFP
(30 min) or their recycling (3 h), based on previous time course
ﬁndings.
DATA ANALYSIS
Results are presented as mean ± SEM. Radioligand binding data
were ﬁtted by non-linear regression to a one-site competition
equation using a least-square method (Prism 4.0, GraphPad Soft-
ware Inc., San Diego, CA, USA) and IC50 values calculated from
this procedure. The same computer program was used to draw
concentration-effect curves (least square ﬁtting of sigmoidal dose-
response equation with variable slope) and to derive contractile
EC50 values. The qualitative effect of treatments on the distri-
bution of the B2R-GFP ﬂuorescent protein (either located at the
plasma membrane or submitted to internalization) was evaluated
for each HEK 293 cell in large microphotographic records and
proportion of affected cells were compared using the χ2 statistics
to determine drug effect on the subcellular receptor distribution.
RESULTS
POTENTIAL ACE SUBSTRATES
BK-Ser-Tyr, BK-His-Leu, and BK-Ala-Pro exhibited a very low
afﬁnity (IC50 values 102-, 363-, and 593-fold greater than that of
unlabeled BK, respectively) for recombinant B2R-GFP, as assessed
by the binding competition of [3H]BK (Figure 2A; numerical
values in Table 1). This assay was performed on ice in the presence
of captopril (see Materials and Methods), thus in the absence of
metabolic interference from ACE. By contrast, the afﬁnities of
the four peptides for human recombinant ACE determined by
the binding competition of [3H]enalaprilat was less divergent, the
three extended BK analogs exhibiting a 3.94-, 3.33-, and 2.23-fold
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FIGURE 2 | Competition of the binding of two radioligands at
their respective recombinant molecular target by BK or three
C-terminally extended analogs developed as potential ACE substrates.
(A) Competition of [3H]BK (3 nM) binding to stably expressed B2R-GFP in
HEK 293 cells. (B) Competition of [3H]enalaprilat (2 nM) binding to
transiently expressed human somatic ACE. Results are expressed as the
residual speciﬁc bindings (means ± SE of n duplicate determinations).
lesser afﬁnity vs. BK for the peptidase, respectively (Figure 2B;
Table 1).
The human isolated umbilical vein is a contractile bioassay for
the B2Rs and this tissue does not exhibit endothelium-dependent
vasorelaxation. The three C-terminally extended BK sequences
act as contractile agents in the vein (Figure 3; parameters calcu-
lated from the cumulative concentration-effect curves in Table 2).
BK-Ser-Tyr, BK-His-Leu, and BK-Ala-Pro were 6.9-, 13.5-, and
14.1-fold less potent thanBK, respectively. However, the full block-
ade of ACE in paired tissues (enalaprilat 1 μM) had contrasting
effects on these agents: while the apparent potency of BK was
not changed, that of BK-Ser-Tyr, BK-His-Leu of BK-Ala-Pro was
decreased 3.9-, 18.3-, and 9.8-fold, respectively. These results sup-
port the assumption of a metabolic activation by ACE of latent
B2R agonists, especially for BK-His-Leu and BK-Ala-Pro. The lack
of effect of ACE inhibitors on the apparent potency of BK has
been previously reported in this preparation (Marceau et al., 1994;
Gobeil et al., 1996; Bawolak et al., 2007). In the contractility assay,
the gain of function mediated by endogenous ACE is apparent as
a steeper linear regression in the graph representing contractility
EC50 as a function of binding IC50 (Figure 4).
POTENTIAL DPP IV AND ARGININE CARBOXYPEPTIDASE SUBSTRATES
Arg-Pro-BK, designed as a potential substrate of DPP IV, retained
a high afﬁnity for the B2R (only 1.6-fold less potent than BK;
Figure 5A; Table 1). The umbilical vein contractility assay did
not show a loss of apparent potency in the presence of the
DPP-IV inhibitor NVP-DPP728 (Figure 5B; Table 2). Alterna-
tively, BK could be regenerated by two enzymatic cycles catalyzed
by aminopeptidases widely expressed in blood vessels, such
as aminopeptidase N (Gera et al., 2013b). The aminopeptidase
inhibitor amastatin also failed to modify the contractile effect of
Arg-Pro-BK (Figure 5B; Table 2).
BK-Arg had an afﬁnity 29-fold lower than that of BK for B2Rs,
based on the binding competition of [3H]BK (Figure 5A; Table 1).
In the contractility assay, the potency of BK-Arg is reduced
15-fold in the presence of the inhibitor of Arg-CPs, Plummer’s
inhibitor. This inhibitor did not affect the potency of BK, given
the experimental precision (Figures 5C,D; Table 2). Together,
these observations support the regeneration of BK by endogenous
Arg-CP(s).
AFFINITY OF C-TERMINALLY PROLONGED BK ANALOGS FOR THE KININ
B1R
Bradykinin itself and the three BK analogs prolonged by a
C-terminal dipeptide exhibited a very low afﬁnity (IC50 > 10 μM)
Table 1 | Parameters derived from radioligand binding competition assays.
Agonist [3H]BK binding to B2R-GFP
log(IC50) ± SE
[3H]enalaprilat binding to ACE
log(IC50) ± SE
[3H]Lys-des-Arg9-BK binding to B1R-FLAG
log(IC50) ± SE
BK −7.80 ± 0.10 −5.81 ± 0.12 >−5
BK-Ser-Tyr −5.79 ± 0.13 −5.21 ± 0.15 >−5
BK-His-Leu −5.24 ± 0.20 −5.28 ± 0.22 >−5
BK-Ala-Pro −5.11 ± 0.16 −5.46 ± 0.11 >−5
Arg-Pro-BK −7.61 ± 0.09 – –
BK-Arg −6.34 ± 0.11 – −5.12 ± 0.10
Lys-des-Arg9-BK – – −8.98 ± 0.05
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FIGURE 3 | Contractility studies in the human isolated umbilical vein, a
bioassay for the B2 receptors, for BK and three C-terminally extended
analogs that are potential ACE substrates. (A) Cumulative
concentration-effect curve for BK as modiﬁed by the ACE inhibitor
enalaprilat (1 μM). (B,C) Cumulative concentration-effect curve for
BK-Ser-Tyr (B), BK-His-Leu (C) and BK-Ala-Pro (D) as modiﬁed by the same
drug. The control curves were constructed in the presence of the DMSO
vehicle of enalaprilat. Separate tissues from the same individuals were
used as controls. Values are means ± SE of the number of replicates
indicated between parentheses.
for the recombinant human B1R, as assessed by the binding com-
petition of [3H]Lys-des-Arg9-BK (Figure 6; Table 1). Surprisingly,
BK-Arg had an afﬁnity for the B1R larger than that of BK, but still
marginal (IC50 = 7.6 μM). The unlabeled form of the radioli-
gand efﬁciently competed for receptor binding in the nanomolar
concentration range.
EFFECT OF SELECTED C-TERMINALLY EXTENDED BK HOMOLOG ON
B2R-GFP CYCLING
Human Embryonic Kidney 293 cells stably expressing B2R-GFP
at the level of their plasma membrane exhibited the known
BK-induced internalization of the ﬂuorescent receptor follow-
ing a 30-min stimulation period in the serum-containing culture
medium at 37◦C (100 nM of BK; Figure 7). The cell morphology
in green epiﬂuorescence was that of disrupted plasma membrane
continuity with abundant and polymorphic cytosolic inclusions.
As previously reported, this morphology almost entirely reverted
3 h after BK stimulation, coincident with the disappearance of
immunoreactive BK in the culturemedium (Bachvarov et al., 2001;
Charest-Morin et al., 2013b). This assay was applied to selected
C-terminally extended BK homolog that exert, at 100 nM, lit-
tle or no competition on the binding of [3H]BK to B2R-GFP:
BK-His-Leu (Figure 2A) and BK-Arg (Figure 5A). After 30 min
of treatment with the peptides, the translocation of B2R-GFP-
associated ﬂuorescence from the plasma membrane to endosomes
was moderate for BK-His-Leu, and weaker, but signiﬁcant for
BK-Arg (see χ2 statistics in Figure 7). However, extensive recy-
cling of the ﬂuorescent receptors to the plasma membrane was
also observed at time 3 h post stimulation with the extended BK
sequences. While HEK 293 cells do not express ACE unless trans-
fected with the corresponding expression vector (Morissette et al.,
2008), their serum-supplemented culture medium contains sol-
uble ACE (Bachvarov et al., 2001) and is also likely to contain
soluble Arg-CP activity, at least carboxypeptidase N. The spe-
ciﬁc inhibitors of these peptidases, enalaprilat and Plummer’s
inhibitor, respectively, were applied before 30-min treatment
with the BK-related agonists in additional experiments reported
in Figure 7. While these inhibitors did not inﬂuence the very
high proportion of cells that exhibited BK-induced internaliza-
tion of B2R-GFP, enalaprilat selectively suppressed that induced
by BK-His-Leu and Plummer’s inhibitor signiﬁcantly abated
the effect of BK-Arg (Figure 7), consistent with the metabolic
activation of the two latter agonists by ACE and an Arg-CP,
respectively.
DISCUSSION
Protease-activated prodrugs would produce little off-target side
effects if the distribution of the chosen protease was charac-
teristic of a disease state, e.g., tumors enriched in cathepsins
or matrix metalloproteinases (Choi et al., 2012). Exploiting the
distribution of ectopeptidases expressed in the vasculature to
activate pro-drugs is a novel approach that mimics the natu-
ral ACE-mediated gain of function of Ang I. Effective pro-drugs
that regenerate BK should have little direct afﬁnity at the B2R,
which was tested using the [3H]BK binding competition assay.
Further, BK is the minimal sequence of high afﬁnity at the B2R
and any fragment (e.g., those generated by ACE) will not be
biologically active (Leeb-Lundberg et al., 2005). The current dock-
ing model of BK to the B2R indicates that the N-terminus of
the agonist peptide is close to the extracellular ﬂuid, thus pos-
sibly amenable to N-terminal extension, while the C-terminus of
BK interacts deep in the receptor central cavity (Leeb-Lundberg
et al., 2005), consistent with the more severe loss of afﬁnity for
BK sequences prolonged at the C-terminus in the present novel
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Table 2 | Parameters derived from contractility assays in the human umbilical vein.
Agonist Data from
Figures
Control (DMSO vehicle)
log(EC50) ± SE
Peptidase inhibitor identity +Peptidase inhibitor
log(EC50) ± SE
BK 3A −7.74 ± 0.07 enalaprilat 1 μM −7.82 ± 0.09
BK-Ser-Tyr 3B −6.90 ± 0.09 enalaprilat 1 μM −6.32 ± 0.06
BK-His-Leu 3C −6.61 ± 0.11 enalaprilat 1 μM −5.34 ± 0.06
BK-Ala-Pro 3D −6.59 ± 0.07 enalaprilat 1 μM −5.55 ± 0.06
Arg-Pro-BK 5B −7.39 ± 0.06 NVP-DPP728 1 μM −7.29 ± 0.03
amastatin 3 μM −7.35 ± 0.07
BK 5C −8.47 ± 0.08 Plummer’s inhibitor 1 μM −8.39 ± 0.07
BK-Arg 5D −6.67 ± 0.08 Plummer’s inhibitor 1 μM −5.49 ± 0.07
FIGURE 4 | Relationship between the IC50 values obtained using the
[3H]BK binding competition assay and the contractility EC50 values of
BK analogs that have affinity for ACE as a function of the presence of
the ACE inhibitor enalaprilat in the contractility assay.
series of peptides. For the latter BK analogs, the gain of function
resulting from the regeneration of BK in the venous contrac-
tility assay must follow precise cleavage rules. Pharmacologic
evidence of ACE-mediated removal of the C-terminal dipep-
tide of BK-Ser-Tyr, BK-His-Leu and BK-Ala-Pro was obtained
as enalaprilat reduced the contractile potency of each of these
peptides approximately to the level of its low afﬁnity for B2Rs
(Figure 4). The most favorable design, BK-His-Leu, shares
its C-terminal dipeptide sequence with the known ACE sub-
strate Ang I, displaces [3H]enalaprilat from recombinant ACE
and has an apparent 18-fold gain of function mediated by
ACE in the venous contractility assay. Immunohistochemistry
of human umbilical vein sections showed that ACE expres-
sion is limited to the luminal (endothelial) surface of the vein
(Koumbadinga et al., 2010). BK-His-Leu-induced internalization
of B2R-GFP is selectively suppressed by enalaprilat in HEK 293
cells (Figure 7), a system where ACE is supplied by serum-
containing culture medium (Bachvarov et al., 2001). In this exper-
imental system, the endocytosis of B2R-GFP is largely reversible
as a function of time (compare the 30-min stimulation with the
3-h stimulation in Figure 7), an effect previously attributed in
part to ACE-mediated BK degradation in the culture medium
(Bachvarov et al., 2001). However, the very large acute effect of BK
on the endocytosis of B2R-GFP was not modiﬁed by enalaprilat
co-treatment.
Only the C-terminal residue must be removed from BK-Arg to
regenerate BK and one of the Arg-CPs (kininase I activity) may
mediate this; these peptidases include soluble carboxypeptidase
N, carboxypeptidase M, and carboxypeptidase D, the two latter
being expressed at the surface of human endothelial cells (Sangsree
et al., 2003). Carboxypeptidase N assumes a minor pathway of BK
degradation in human plasma leading to the formation of des-
Arg9-BK (Cyr et al., 2001) as BK itself possesses a C-terminal Arg
residue. Plummer’s inhibitor (mergetpa), a mercapto analog of
Arg (Plummer and Ryan, 1981), blocks Arg-CPs with speciﬁcity
and reduces the effect of Lys-BK on the rabbit aorta, a contrac-
tile bioassay of the kinin B1R, because the in situ formation of
its optimal agonist Lys-des-Arg9-BK depends on kininase I (Gera
et al., 2011). In the present experiments, a loss of BK-Arg contrac-
tile potency in the B2R bioassay and of B2R-GFP endocytosis in
HEK 293 cells in the presence of Plummer’s inhibitor is consistent
withArg-CP-mediated regeneration of BK fromBK-Arg in control
conditions.
The existence of BK regenerated from either type of C-terminal
extended peptides is probably transient in vascular tissue, as the
very same activating peptidases also inactivate intact BK. The recy-
cling of B2R-GFP to the plasma membrane of cells 3 h after stim-
ulation with either BK-His-Leu or BK-Arg is also consistent with
the inherent fragility of the regeneratedBK. By contrast, prolonged
endocytosis (≥12 h) of B2R-GFP is produced in response to sev-
eral inactivation-resistant B2R agonists or partial agonist (Bawolak
et al., 2009, 2012). ACE inhibitors exert differential effects in the
BK bioassays used in the present study: while captopril increases
BK half-life in the culture medium of HEK 293 cells and the
duration of B2R-GFP endocytosis in these cells (Bachvarov et al.,
2001), enalaprilat or captopril failed to potentiate BK in the human
umbilical vein contractility assay (Figure 3A; Marceau et al., 1994;
Gobeil et al., 1996; Bawolak et al., 2007). The latter ﬁnding does
not automatically apply to all isolated blood vessels, as the BK
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FIGURE 5 | Pharmacology of Arg-Pro-BK, a potential DPP IV substrate,
and of BK-Arg, an arginine carboxypeptidase substate. (A) Competition
of [3H]BK (3 nM) binding to stably expressed B2R-GFP in HEK 293 cells.
(B) Cumulative concentration-effect curve for Arg-Pro-BK as modiﬁed by
the DPP IV inhibitor NVP-DPP728 (1 μM) or the aminopeptidase inhibitor
amastatin (3 μM). (C) Lack of effect of Plummer’s inhibitor on BK-induced
contraction of the human umbilical vein preparation. (D) Cumulative
concentration-effect curve for BK-Arg as modiﬁed by the same drug.
Presentation as in Figures 2 and 3.
contractile effect on the rabbit isolated jugular vein was clearly
potentiated by enalaprilat treatment (Gera et al., 2011). Previous
immunohistochemistry and immunoﬂuorescence studies showed
that the umbilical vein possesses a relatively thickmedia composed
of ∼30 layers of compactly organized smooth muscle cells (posi-
tive for α-actin), while immunoreactive ACE is represented in the
FIGURE 6 | Competition of [3H]Lys-des-Arg9-BK (1 nM) binding to
transiently expressed human B1R (B1R-FLAG vector) in HEK 293a cells
by C-terminally prolonged BK analogs. For comparison, unlabeled BK
and Lys-des-Arg9-BK, the prototypical agonists of the B2R and B1R,
respectively, were also used as competitors. Results are expressed as the
residual speciﬁc bindings (means ± SE of three duplicate determinations).
single endothelial cell layer (Koumbadinga et al., 2010; Gera et al.,
2013b). By comparison, the rabbit jugular vein is very thin, with a
higher endothelium/smooth muscle ratio. In the human umbilical
vein preparation, due to the low endothelium/muscle ratio, ACE
activity may not impair the equilibrium between BK concentra-
tion in the bathing ﬂuid and that at the vicinity of most venous
muscle cells (the general problem of non-equilibrium drug dis-
tribution in isolated vascular tissue is discussed by Marceau et al.,
2010). However, ACE presence in the umbilical vein is function-
ally revealed by the metabolic activation of prodrug peptides that
regenerate BK.
We have previously explored several N-terminal extensions of
kinin sequences to produce conjugates with ﬂuorophores, drug-
like molecules and an antigenic tag (Gera et al., 2012, 2013a).
These agents were generally afﬂicted by a severe loss of afﬁnity
(2–3 log units), although other N-terminally extended sequences
(Met-Lys-BK, maximakinin, the GFP-maximakinin fusion pro-
tein) retain excellent afﬁnities at the B2R (Bawolak et al., 2012;
Charest-Morin et al., 2013a). This was also the case for the novel
analog Arg-Pro-BK, designed as a DPP IV substrate (Figure 1).
The conserved afﬁnity of Arg-Pro-BK for the B2R precludes the
observation of an activation reaction in the venous contractility
system. However, the latter may contain such aminopeptidases: we
have recently observed that L-Ala-histamine-induced contraction
of the isolated umbilical vein largely results from the regenera-
tion of free histamine by aminopeptidase(s) sensitive to amastatin
(Gera et al., 2013b), thus extending the concept of vasopeptidase-
activated prodrug to another receptor system (the histamine H1
receptor).
Current evidence favors the preformed B2R over the inducible
B1R as the pharmacological entity that mediates most cardiovas-
cular beneﬁts of kinins (see Introduction). The novel C-terminally
extended BK analogs have little or no direct afﬁnity for the
B1R (Figure 6) and are not likely to release signiﬁcant amounts
of a human B1R agonist for the following reasons: (1) the
optimal agonist of the human form of the B1R is Lys-des-Arg9-
BK, not des-Arg9-BK which has little afﬁnity (Leeb-Lundberg
et al., 2005). The designed prodrug peptides are all based on
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FIGURE 7 | Effect of BK-related peptides (100 nM) added to the
serum-supplemented culture medium of HEK 293 stably expressing
B2R-GFP on the cycling of this fusion protein. Green epiﬂuorescence
(original magniﬁcation 1000×). The effect of co-treatment with peptidase
inhibitors is shown for the shorter incubation period (30 min). The effect of
each experimental condition on the proportion of cells showing evidence of
B2R-GFP internalization was evaluated using χ2 statistics relative to the
control condition indicated by arrows (either control cells for vertical arrows,
or the left-most conditions for horizontal arrows; *P < 10−3, N. S.
non-signiﬁcant).
BK, not Lys-BK, and cannot generate Lys-des-Arg9-BK. (2) It
is not excluded that they indirectly produce small amounts of
des-Arg9-BK from regenerated BK in the umbilical vein. How-
ever, authentic BK is competitively antagonized by various B2R
antagonists in this bioassay, not by a selective B1R antagonist
(Marceau et al., 1994; Gobeil et al., 1996; Bawolak and Marceau,
2007), showing that des-Arg9-BK, if generated from BK, does
not reach pharmacologically active concentrations. (3) B1R-
mediated contraction in the human umbilical vein starts from
a low maximal effect that increases as a function of the incuba-
tion time, being weak 2 h post-tissue mounting and more intense
at the time point 5 h (Houle et al., 2000). By contrast, the con-
tractile effect mediated by the B2R is stable (2–6 h; Marceau
et al., 1994). Thus any contribution of the B1R to the effects of
C-terminally extendedBKs is unlikely in the umbilical vein assay as
applied.
BK-His-Leu and BK-Arg are examples of pro-drug B2R ago-
nist peptides activated by peptidases expressed in vascular tissue
and blood plasma. Thus, novel peptides extended around the BK
sequence behave as peptidase-activated B2R agonists that may be
selective for the vascular system and support further investigation
of the cardiovascular beneﬁts of kinins.
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